Figure 3. in vivo evaluation of LbL-targeted QD₈₀₀ core NPs.

(A) Representative live-animal imaging of LbL-targeted QD₈₀₀ core NPs following systemic administration to 143B osteosarcoma xenograft-bearing NCR nude mice. Imaging conducted at λ_ex = 640 nm, λ_em = 800 nm for up to 8 days. Hind-flank xenografts identified in the pre-injection image; arrows at 5 minutes and 9 hours indicate binding to native bone tissue. (B) Quantification of fold tumor-specific accumulation normalized to tissue auto-fluorescence pre-injection for the systemically administered LbL-targeted QD₈₀₀ core NPs, as visualized in (A). n = 3 mice (6 tumors); data presented as mean +/− SEM. (C) Biodistribution data corresponding to endpoint of (A) (quantified as percent recovered fluorescence following harvest of relevant tissue after 8 days post-administration). n = 3 mice (6 tumors); data presented as mean +/− SEM. (D) Co-localization of QD₈₀₀ NP core with LbL-film containing labeled PAA-Alendronate₇₀₀; top row [PAA-Alendronate₇₀₀ channel] – imaging conducted at λ_ex = 640 nm, λ_em = 700 nm, bottom row [QD₈₀₀ channel] - imaging conducted at λ_ex = 640 nm, λ_em = 800 nm.